Bienvenido al foro!
Parece que has estado leyendo durante un rato.
Si te registras, podrás marcar lo que ya has leído y te podemos avisar cuando hayan nuevos comentarios.
También podrás participar escribiendo tus comentarios y hacer preguntas.
Si quieres participar, puedes registrarte, sólo tardarás 1 minuto.
C8 MediSensors Optical Glucose Monitor™ System
for People with Diabetes
A new non-invasive continuous glucose monitor is approved for marketing in Europe
We are pleased to contact you with our latest news: C8 MediSensors, Inc. has received
CE Mark approval for its Optical Glucose Monitor System. Our new non-invasive continuous glucose monitor (nCGM), will be marketed in Europe.
The comprehensive, 10-year Diabetes Control and Complications Trial (DCCT) clearly demonstrated that individuals with type 1 diabetes who kept blood glucose levels as close to normal as possible for as long as possible had less chance of developing disease-related complications. The DCCT found that the risk of eye disease was reduced by 76%, kidney disease by 50% and nerve disease by 60%. Since that time, other studies have confirmed the importance of tight glycaemic control with minimal glucose excursions in reducing disease-related complications not only in type 1 diabetes, but also in type 2.[2-6]
In addition, a large number of studies have shown that continuous glucose monitors (CGM) can improve glycaemic control with reduced risk of hypoglycaemia.[7-19] CGMs are adjunct devices that are intended to complement finger stick blood glucose tests. Traditional CGMs rely on a needle sensor inserted under the skin, which can cause pain or discomfort, and pose a risk of infection. In contrast, the C8 MediSensors Optical Glucose Monitor System harnesses the power of light to measure glucose levels. Using Raman spectroscopy, a beam of light is shone into the skin and the resulting vibrations of glucose molecules are measured to give a glucose reading; all achieved via a small, pain-free portable monitor, discreetly worn under clothes against the skin.
For added convenience these readings are stored and sent wirelessly to the user’s smartphone for glucose readings at a glance, providing the wearer with a continuous picture of glucose dynamics throughout the day. A good understanding of glucose levels is invaluable in managing diabetes and improving patient outcomes. In clinical studies, the C8 MediSensors monitor was found to have accuracy comparable to earlier versions of invasive CGMs when those systems were first introduced, but with less pain and less risk of infection.
“C8 MediSensors was co-founded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease,” said Paul Zygielbaum, CEO of C8 MediSensors. “CE Mark approval is a landmark step for this unique technology. Our team is hugely excited to be working to make nCGM and the Optical Glucose Monitor System available throughout Europe.”
The C8 MediSensors Optical Glucose Monitor System is not yet shipping but will soon be available for purchase online via the C8 MediSensors website, www.c8medisensors.com.
The C8 MediSensors Optical Glucose Monitor System is an adjunct device. It is contraindicated in pregnancy and for those under 18 years of age, as well as in individuals with very light or very dark skin tones, peripheral vascular disease or individuals who smoke.